MapLight Therapeutics, Inc.

NASDAQ:MPLT

Biotechnology

Healthcare
$6.57 +3.11%

+$0.39 today

Market cap
$280.00M
Beta
2.65
P/E (TTM)
-2.8
EPS (TTM)
-$4.41
52W Low $9.10High $40.43

Volume 0.55M

Average 0.73M

Returns on capital

MapLight Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management

ROE

-35.2%

avg -81.1%

ROIC

-36.4%

avg -73.5%

ROA

-33.6%

avg -56.9%

Analysis

ROA is currently the strongest return metric at -33.6% versus its period average of -56.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Christopher A. Kroeger

Founder, President, Chief Executive Officer & DirectorUSD 1.01M581.20M2.81%

Erin Pennock Foff

Chief Medical OfficerUSD 745.85K49296.91K0.70%

Karl Deisseroth

Co-Founder & Member of Scientific Advisory BoardUSD 147.36K———

Robert C. Malenka

Co-Founder & Member of Scientific Advisory BoardUSD 147.36K71——

Anatol Kreitzer

Chief Discovery Officer—51168.68K0.40%

Karoly Nikolich

Founder & Member of Advisory Board—78——

Jonathan Gillis

Chief Admin & Acc Officer, PAO, Interim CFO & PFO—45142.31K0.33%

James Woodruff Lillie

Chief Scientific Officer—70198.60K0.47%

Kristopher L. Hanson

General Counsel & Secretary—54——

Compensation is shown in the reported currency; data updated Nov 14, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 15, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

7

$65.54M

Sells

52

$12.71M

Net Transaction Value

+$52.82M

Net buying

Most Active

Foff Erin Pennock

10 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Oct 15, 26

Foff Erin Pennock

Direct

Sell$124.1K
Oct 15, 26

Kroeger Christopher A.

Direct

Sell$595.4K
Oct 15, 26

GILLIS JONATHAN

Direct

Sell$82.1K
Oct 15, 26

Lillie James Woodruff

Direct

Sell$93K
Oct 15, 26

Kreitzer Anatol

Direct

Sell$96K
Oct 15, 26

Hanson Kristopher

Direct

Sell$72.9K
Sep 16, 26

Hanson Kristopher

Direct

Sell$192.7K
Aug 14, 26

Catalyst4, Inc.

Indirect

Buy$50.1M
Aug 14, 26

Catalyst4, Inc.

Indirect

Buy$292.9
Aug 3, 26

Lillie James Woodruff

Direct

Sell$276.9K

1–10 of 59

Summary

Insiders reported 7 buys worth $65.54M and 52 sells worth $12.71M over the last 12 months. That adds up to net buying of $52.82M. Foff Erin Pennock was the most active insider with 10 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A3 analysts
RevenueN/AN/AN/A
N/A4 analysts
Net IncomeN/AN/AN/A
N/A4 analysts
EBITN/AN/AN/A
N/A4 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does MapLight Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about MPLT's management, answered from reported figures.

Who manages MPLT?

MapLight Therapeutics, Inc. (MPLT) lists 9 active executives. The top listed executive is Anatol Kreitzer, Chief Discovery Officer.

Are MPLT insiders buying or selling?

Recent insider activity shows net buying of $59.19M.